NovoCure Ltd

Overview

Compare with UFP Technologies, iRhythm Holdings, Inc. or Bioventus Inc., or pick any stock.

• TickerNVCR on Nasdaq¹
• IndustrySurgical & Medical Instruments & Apparatus¹
• Business addressNo. 4 The Forum, Grenville Street, St. Helier²
• Filer categoryLarge accelerated filer²

See how the biggest companies compare on our leaderboards

We are a global oncology company with a proprietary platform technology called Tumor Treating Fields ("TTFields"), which are electric fields that exert physical forces to kill cancer cells. Our therapy is delivered through a medical device. Our key priorities are to drive commercial adoption of Optune Gio ® , Optune Lua ® , and Optune Pax ® , our commercial TTFields therapy devices, obtain regulatory approval to market TTFields therapy devices in new indications, such as brain metastases from non-small cell lung cancer ("NSCLC"), and to advance clinical and product development programs intended to extend overall survival in some of the most aggressive forms of cancer.⁴ From its latest annual report

Corporate structure

NovoCure Ltd sits at the top of its group. 18 entities, 16 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What NovoCure Ltd reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Inventory

Properties, in its own words

Our global headquarters and operating center is located in Baar, Switzerland, our U.S. flagship location and our operating center/warehouse are located in Portsmouth, New Hampshire, and our research and development operations are located in Haifa, Israel, all of which are leased, except for the U.S. flagship location, which we purchased in 2021 and became operational in 2024. We also lease additional office and warehouse space across North America, Europe, Israel and Japan. We believe that our current facilities are adequate for our present purposes, but we may need additional space as we continue to grow and expand our operations. We believe that suitable additional or alternative office, laboratory, and manufacturing space would be available as required in the future on commercially reasonable terms.

Item 2 of the 10-K filed Feb 26, 2026.⁴

Leadership

Who has led NovoCure Ltd, and when. Pick a name to see everywhere that person has worked.

• Chief executive officerAshley Cordova Jan 3, 2025 to now¹³
• Chief executive officerAsaf Danziger Oct 1, 2015 to Aug 6, 2024¹⁴
• Chief financial officerChristoph Brackmann Jan 6, 2025 to now¹⁵
• Chief financial officerAshley Cordova Sep 4, 2020 to Aug 6, 2024¹⁶
• Chief financial officerWilhelmus Cm Groenhuysen Oct 1, 2015 to Jul 8, 2020¹⁷
• Chief operating officerMukund Paravasthu Oct 9, 2024 to now¹⁸
• Chief operating officerWilhelmus Cm Groenhuysen Sep 3, 2020 to Aug 6, 2024¹⁹
• Chief operating officerMichael J. Ambrogi Oct 1, 2015 to Jul 23, 2020²⁰

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

• NovoCure (Israel) Ltd. Israel³
• NovoCure GmbH Germany³
• Novocure Austria GmbH Austria³
• Novocure Belgium S.r.l. Belgium³
• Novocure Canada, Inc. Canada³
• Novocure Capital S.à.r.l. Luxembourg³
• Novocure Denmark ApS Denmark³
• Novocure France SAS France³
• Novocure Inc. Delaware³
• Novocure Italy S.r.L. Italy³
• Novocure K.K. Japan³
• Novocure Luxembourg S.à.r.l. Luxembourg³
• Novocure Netherlands B.V. Netherlands³
• Novocure Poland Sp. z o.o. Poland³
• Novocure Singapore Pte. Ltd. Singapore³
• Novocure Spain S.L. Spain³
• Novocure Sweden AB Sweden³
• Novocure UK Limited United Kingdom³
• Novocure USA LLC Delaware³

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Timeline

1. Oct 1, 20268-K Regulation FD disclosure⁴⁶
2. Sep 9, 20268-K Executive or director change⁴⁷
3. Sep 1, 20268-K Other events⁴⁸
4. Jul 23, 20268-K Results of operations⁴⁹
5. Jun 30, 20268-K Regulation FD disclosure⁵⁰
6. Jun 18, 20268-K Regulation FD disclosure⁵¹
7. Jun 5, 20268-K Executive or director change; Shareholder vote⁵²
8. Apr 30, 20268-K Results of operations⁵³
9. Apr 24, 20268-K Executive or director change⁵⁴
10. Apr 9, 20268-K Executive or director change⁵⁵
11. Mar 26, 20268-K Regulation FD disclosure⁵⁶
12. Feb 26, 20268-K Results of operations⁵⁷
13. Jan 3, 2025New chief executive Ashley Cordova becomes CEO¹³
14. Oct 1, 2015New chief executive Asaf Danziger becomes CEO¹⁴

Calendar

Coming up

1. Oct 29, 2026 · Before the openReports results for the quarter ending Sep/2026 A year earlier it reported ($0.33) a share, on Oct 30, 2025.⁵⁸

When it reported results

1. Jul 23, 2026Reported quarterly or annual results⁴⁹
2. Apr 30, 2026Reported quarterly or annual results⁵³
3. Feb 26, 2026Reported quarterly or annual results⁵⁷
4. Jan 12, 2026Reported quarterly or annual results⁵⁹
5. Oct 30, 2025Reported quarterly or annual results⁶⁰
6. Jul 24, 2025Reported quarterly or annual results⁶¹
7. Apr 24, 2025Reported quarterly or annual results⁶²
8. Feb 27, 2025Reported quarterly or annual results⁶³

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

454 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 72 major events, 255 insider forms, 33 large holders, 74 other. The latest 20:

1. Oct 1, 20268-K EDGAR
2. Sep 9, 20268-K EDGAR
3. Sep 1, 20268-K EDGAR
4. Jul 23, 2026144 EDGAR
5. Jul 23, 20268-K EDGAR
6. Jul 23, 202610-Q EDGAR
7. Jul 1, 20264 PRIMARY DOCUMENT EDGAR
8. Jul 1, 20264 PRIMARY DOCUMENT EDGAR
9. Jul 1, 20264 PRIMARY DOCUMENT EDGAR
10. Jul 1, 20264 PRIMARY DOCUMENT EDGAR
11. Jun 30, 20268-K EDGAR
12. Jun 18, 20268-K EDGAR
13. Jun 5, 20264 PRIMARY DOCUMENT EDGAR
14. Jun 5, 20264 PRIMARY DOCUMENT EDGAR
15. Jun 5, 20264 PRIMARY DOCUMENT EDGAR
16. Jun 5, 20264 PRIMARY DOCUMENT EDGAR
17. Jun 5, 20268-K EDGAR
18. Jun 5, 20264 PRIMARY DOCUMENT EDGAR
19. Jun 5, 20264 PRIMARY DOCUMENT EDGAR
20. Jun 5, 20264 PRIMARY DOCUMENT EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

147 open-market trades by officers, directors and large owners since October 2021: 3 buys and 144 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Soleus Capital Master Fund, L.P.SCHEDULE 13G/A, 5 filings Apr 1, 2025 to May 8, 2026⁶⁴
• VANGUARD PORTFOLIO MANAGEMENT LLCSCHEDULE 13G, 1 filing Apr 28, 2026⁶⁵
• VANGUARD GROUP INCSCHEDULE 13G/A, 5 filings Feb 10, 2022 to Mar 26, 2026⁶⁶
• Capital World InvestorsSCHEDULE 13G/A, 6 filings Feb 11, 2022 to Nov 13, 2025⁶⁷
• Capital International InvestorsSCHEDULE 13G/A, 4 filings Feb 11, 2022 to Jul 7, 2025⁶⁸
• BlackRockSCHEDULE 13G/A, 5 filings Feb 3, 2022 to Apr 23, 2025⁶⁹
• FMR LLCSC 13G/A, 4 filings Feb 9, 2022 to Feb 9, 2024⁷⁰
• BAILLIE GIFFORD & COSC 13G/A, 3 filings Jan 26, 2022 to Nov 9, 2023⁷¹

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

SEC filer profile

How NovoCure Ltd is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARNovoCure Ltd¹
• CIK0001645113
• Employer ID (EIN)98-1057807⁴
• Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company⁴
• Incorporated inJersey⁴
• Fiscal year endsDecember 31¹
• Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus¹
• SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance¹
• Business addressNo. 4 The Forum, Grenville Street, St. Helier, Jersey¹
• Phone44 (0)15 3475 6700¹
• Shares outstanding116,445,840 as of Jul 17, 2026⁵
• Public float$995.0M as of Jun 30, 2025⁴
• AuditorKOST FORER GABBAY & KASIERER, Israel PCAOB ID 1281; it also attests to the company’s internal control over financial reporting⁴
• On EDGAR sinceJun 24, 2015¹
• Filings1,170 in all: 4 (722), 8-K (152), SC 13G/A (43), 3 (39), 144 (37), 10-Q (33), S-8 POS (16), DEFA14A (12)¹
  All 37 form types

  10-K (11), 4/A (11), DEF 14A (11), S-8 (11), SC 13G (11), SCHEDULE 13G/A (8), UPLOAD (8), CORRESP (6), 10-Q/A (5), 5 (3), PRE 14A (3), SC 13D/A (3), SCHEDULE 13G (3), 10-K/A (2), 3/A (2), 8-K/A (2), CT ORDER (2), S-1/A (2), SC 13D (2), 424B1 (1), 424B3 (1), 8-A12B (1), CERTNAS (1), DEFR14A (1), DRS (1), DRS/A (1), DRSLTR (1), EFFECT (1), S-1 (1)

• Latest filingsAnnual report (10-K) Feb 26, 2026
  Quarterly report (10-Q) Jul 23, 2026
  Proxy statement (DEF 14A) Apr 20, 2026
  Latest 8-K (8-K) Oct 1, 2026

Securities registered for trading

From the cover page of the 10-K filed Feb 26, 2026 (Section 12(b) of the Exchange Act).⁴

Risk factors and legal proceedings

The risks NovoCure Ltd names in Item 1A of its 10-K filed Feb 26, 2026: 39 risks under these headings, as written.⁴

• Risks relating to our business and our Products
• Our business and prospects depend heavily on Optune Gio, which is currently approved only for the treatment of GBM, Optune Lua, which is currently approved for the treatment of NSCLC and MPM in certain countries and Optune Pax, which is currently approved for the treatment of pancreatic cancer in the U.S. If we are unable to increase sales of our Products, obtain further regulatory approvals and commercialize our Products for the treatment of additional indications, or are significantly delayed or limited in doing so, our business and prospects will be materially harmed.
• To date, we have generated only occasional and intermittent operating profits, and we have a history of incurring substantial operating losses.
• Our clinical studies could be delayed or otherwise adversely affected by many factors, including difficulties in enrolling patients.
• If we are unable to continue the development of an adequate sales and marketing organization or contract with third parties to assist us, we may not be able to successfully commercialize our Products for current and future indications.
• The success of our business may be dependent on the actions of our collaborative partners.
• We may not be successful in achieving market acceptance of our Products by healthcare professionals, patients and/or third-party payers in the timeframes we anticipate, or at all, which could have a material adverse effect on our business, prospects, financial condition and results of operations.
• Failure to secure and maintain adequate coverage and reimbursement from third-party payers could adversely affect acceptance of our Products and reduce our revenues.
• We may not be successful in securing and maintaining reimbursement codes necessary to facilitate accurate and timely billing for our Products or physician services attendant to our Products.
• There is no assurance that Medicare or the Medicare Administrative Contractors will provide, or continue to provide, coverage or adequate payment rates for our Products.
• We depend on single-source suppliers for some of our components. The loss of these suppliers could prevent or delay shipments of our Products, delay our clinical studies or otherwise adversely affect our business.
• Quality control problems with respect to devices and components supplied by third-party suppliers could have a material adverse effect on our reputation, our clinical studies or the commercialization of our Products and, as a result, a material adverse effect on our business, prospects, financial condition and results of operations.

Legal proceedings

From time to time, we are involved in various legal proceedings, claims, investigations and litigation that arise in the ordinary course of our business. Litigation is inherently uncertain. Accordingly, we cannot predict with certainty the outcome of these matters. After considering a number of factors, including (but not limited to) the views of legal counsel, the nature of contingencies to which the Company is subject and prior experience, management believes that the ultimate disposition of these legal actions will not materially affect its consolidated financial position or results of operations.

The opening of Item 3, Legal Proceedings.⁴